vialroom

#oral-glp1 2025-11-08

Saturday42 messages11 participantstimes are UTC
Highlights from this day
  • two_labs_two_answers — i have never lied about it. i have simply never mentioned it 17:34
  • tarpit_tam — 36 weeks, mid teens percent weight reduction at the higher doses. thats a phase 2 result and it was better than most people expected from a small molecule 17:37
  • ferrous_ash — thats the most important sentence anybody has typed in this channel 18:13
  • tarpit_tam — boring wins more often than impressive does 20:03

did anyone go back to injecting after trying oral

absorption is the variable, not the molecule. same tablet, different morning, different result

peptidemeter-summary-e-2205.pdf
2 pages · 930 KB · not retained in the public archive
NS

orforglipron is a small molecule rather than a peptide, which is why the fasting conditions differ
absorption is the variable, not the molecule. same tablet, different morning, different result

i was wrong about the water amount, i was using a sip and it needs a lot more than that

😂9🧪2
RR

PIONEER was the original oral semaglutide programme and OASIS looked at the higher oral doses

TT

update on the earlier thing anyone tracking whether their oral results line up week to week
i said 5 months ago that my oral results were random, they got consistent once i fixed the water

transit-times.csv
433 rows · not retained in the public archive
SS

orforglipron is the one that keeps getting called a game changer. why

its a small molecule GLP-1 receptor agonist. so it does not need SNAC, does not need a fasting window, and does not care about water

TT

same receptor, different binding chemistry. non peptide agonists sit differently but activate it

BB

the no rules part is the whole story for adherence. everyone in this channel has broken the 30 minute rule and lied about it

TT

Cited study
Orforglipron phase 2 — once-daily oral non-peptide GLP-1 receptor agonist in obesity
NEJM · 2023
36 weeks, dose ranging, no food or water restrictions

36 weeks, mid teens percent weight reduction at the higher doses. thats a phase 2 result and it was better than most people expected from a small molecule

TT

the obesity phase 3 programme has reported and the results were broadly consistent with phase 2. i would rather people read it than take my summary

BB

which is the correct instinct and also why we cite journal and year for everything in here

TT

on weight, no, not at present. the injectables and especially the dual and triple agonists are ahead on the mean

on the chance that a real person takes it correctly every day for three years, possibly by a mile

FA

thats the most important sentence anybody has typed in this channel

💯12🎯5
TT

right. peptide supply has been the bottleneck for years, and small molecules do not have that bottleneck

BB

not really, and be very careful. anything sold as orforglipron in the grey market right now deserves maximum suspicion

TL

the analytical picture is different too. its not a peptide, so a standard peptide purity assay is the wrong test entirely

TT

correct. you would want a small molecule method. sending it to a lab expecting a peptide COA gets you a meaningless number

TL

for reference the legitimate large scale peptide houses like Bachem Holding have never pretended to be a route to this. they make peptides

FA

and the standing reminder — nothing in this channel is approved for you to take, and nobody here is telling you to take anything

BB

on the real world data, yes. a lot of people stop in the first year and the reasons are rarely the ones trials measure

SS

back. and thats the whole argument for a boring pill with no rules